InvestorsObserver
×
News Home

Lipocine Inc (LPCN) Stock: What Does the Chart Say?

Monday, November 30, 2020 01:13 PM | InvestorsObserver Analysts

Mentioned in this article

Lipocine Inc (LPCN) Stock: What Does the Chart Say?

Lipocine Inc (LPCN) stock has risen 7.43% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bullish
Lipocine Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LPCN!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With LPCN Stock Today?

Lipocine Inc (LPCN) stock has fallen -0.62% while the S&P 500 is unmoved 0% as of 1:07 PM on Monday, Nov 30. LPCN is down -$0.01 from the previous closing price of $1.60 on volume of 1,126,090 shares. Over the past year the S&P 500 has risen 16.84% while LPCN has risen 261.36%. LPCN lost -$0.44 per share in the over the last 12 months.

To screen for more stocks like Lipocine Inc click here.

More About Lipocine Inc

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO, is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148 and LPCN 1107.

Click Here to get the full Stock Score Report on Lipocine Inc (LPCN) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App